$1250 | Single User
$1800 | Site License
$2500 | Global License

Stimulant Abuse Deterrents and Treatments: An Assessment of the Technological, Competitive and R&D Landscape - H1 2020
[Lowest Price Guaranteed: $1,250]

Published by Gervano R A: 20 Jan 2019 | 270546 | In Stock
Related Topics: Clinical Trials , Drug

Introduction

GervanoRA's pipeline analysis and opportunity assessment report "Abuse Deterrents: Pipeline Analytics, H2 2020" analyzed and assessed the pipeline molecules for Abuse Deterrents along with Stimulant Addiction (Cocaine and Methamphetamine) Market Overview by considering the global scenarios, epidemiology and proposed treatments for the Stimulant Addiction. The report also provides information related to Stimulant Abuse and Deterrence, factors affecting, treatments and impact on Health, Social and Economy through Stimulant Abuse. The Report also focuses on the global trends, recent developments and technologies like the formulation strategies and formulation technologies. For a good understanding about the report we have provided the Pipeline Analysis for Abuse Deterrents based on two segments- Cocaine and Methamphetamine Drug Abuse Deterrent and Stimulant Drug Abuse Deterrent. We have in turn segmented the Chapter with respect to the Highest Stage of development, Geography, Route of Administration, Drug Class and Mechanism of Action.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

• Unmet needs and Opportunities

• Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)

• Estimated Pipeline Drug Approval Time lines

• Clinical Trials Summary

• Current and Future Competitive Landscape

• Key Company Profiles with SWOT Analysis

• Pipeline Drug Descriptions along with Development milestones (Past and Future)

• University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.

Table of Contents
for Stimulant Abuse Deterrents and Treatments: An Assessment of the Technological, Competitive and R&D Landscape - H1 2020

  • TABLE OF CONTENTS

    1. INTRODUCTION

    • 1.1. REPORT DESCRIPTION

    • 1.2. METHODOLOGY

    • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS

    • 1.4. ABOUT US: GERVANORA DATA SERVICES

    2. EXECUTIVE SUMMARY

    • 2.1. REPORTS MAJOR FINDINGS

    • 2.2. KEY PIPELINE EVENTS 2018 TO 2034

    3. STIMULANT ADDICTION (COCAINE & METHAMPHETAMINE) MARKET OVERVIEW

    • 3.1. STIMULANT ADDICTION OVERVIEW

    • 3.2. STIMULANT ADDICTION GLOBAL SCENARIOS

    • 3.3. STIMULANT ADDICTION EPIDEMIOLOGY

    • 3.4. EPIDEMIOLOGY FORECAST

    o 3.4.1. FORECAST METHODOLOGY AND ASSUMPTION

    o 3.4.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

    • 3.5. STIMULANT ADDICTION PROPOSED TREATMENTS

    4. STIMULANT ABUSE OVERVIEW

    • 4.1. STIMULANT ABUSE AND DETERRENCE

    • 4.2. FACTORS AFFECTING ON STIMULANT ABUSE

    • 4.3. EFFECTS AND SYMPTOMS OF STIMULANT ABUSE

    • 4.4. CURRENT TREATMENTS OF STIMULANT ABUSE

    • 4.5. STIMULANT ABUSE - IMPACT ON HEALTH, SOCIAL AND ECONOMY

    5. ABUSE DETERRENT DEALS OVERVIEW

    • 5.1. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)

    o 5.1.1. COLLABORATION AGREEMENTS

    o 5.1.2. LICENSING AGREEMENTS

    o 5.1.3. TERMINATION AGREEMENTS AND SETTLEMENTS

    o 5.1.4. FUNDING & CONTRACTS

    o 5.1.5. PARTNERSHIPS

    o 5.1.6. ACQUISITIONS

    6. STIMULANT ABUSE DETERRENTS-RECENT DEVELOPMENTS AND TECHNOLOGIES

    • 6.1. STIMULANT ABUSE DETERRENT FORMULATION STRATEGIES

    • 6.2. STIMULANT ABUSE DETERRENT FORMULATION TECHNOLOGIES

    • 6.3. INTERNATIONAL GUIDELINES FOR ABUSABLE SUBSTANCES

    • 6.4. UNMET MEDICAL NEEDS AND GAPS IN THE TREATMENT OF STIMULANT ABUSE

    • 6.5. STIMULANT ABUSE GLOBAL TRENDS AND REGULATORY DEVELOPMENTS

    • 6.6. LIMITATIONS OF STIMULANT ABUSE DETERRENT FORMULATIONS

    7. PIPELINE ANALYSIS OF COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT

    • 7.1. THERAPEUTICS UNDER DEVELOPMENT BY STAGE OF DEVELOPMENT

    o 7.1.1. PHASE II MOLECULES

    o 7.1.2. PHASE I MOLECULES

    o 7.1.3. PRECLINICAL MOLECULES

    o 7.1.4. EARLY R&D MOLECULES

    o 7.1.5. INACTIVE MOLECULES

    • 7.2. PIPELINE ANALYSIS BY GEOGRAPHY

    • 7.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

    • 7.4. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES

    8. PIPELINE ANALYSIS OF STIMULANT DRUG ABUSE DETERRENT

    • 8.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT

    o 8.1.1. PRE-REGISTRATION (FILED) MOLECULES

    o 8.1.2. PHASE III MOLECULES

    o 8.1.3. PHASE II MOLECULES

    o 8.1.4. PHASE I MOLECULES

    o 8.1.5. PRECLINICAL MOLECULES

    o 8.1.6. EARLY R&D (DISCOVERY) MOLECULES

    • 8.2. PIPELINE ANALYSIS BY GEOGRAPHY

    • 8.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

    • 8.4. PIPELINE ANALYSIS BY DRUG CLASS

    • 8.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION

    • 8.6. PIPELINE ANALYSIS BY COMPANIES, UNIVERSITIES & INSTITUTES

    9. ESTIMATED DRUG APPROVAL TIMELINES

    • 9.1. METHODOLOGY

    • 9.2. STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS

    o 9.2.1. UNITED STATES (FDA) ESTIMATIONS

    o 9.2.2. EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS

    • 9.3. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS

    o 9.3.1. UNITED STATES (FDA) ESTIMATIONS

    o 9.3.2. EX-UNITED STATES (EMA AND INTERNATIONAL) ESTIMATIONS

    10. CLINICAL TRIAL SUMMARY

    • 10.1. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT

    o 10.1.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS

    o 10.1.2. ONGOING CLINICAL TRIALS SUMMARY

    o 10.1.3. PLANNED CLINICAL TRIAL SUMMARY

    o 10.1.4. RECENTLY COMPLETED CLINICAL TRIALS

    • 10.2. STIMULANT DRUG ABUSE DETERRENT

    o 10.2.1. PIPELINE ANALYSIS BY CLINICAL TRIAL RESULTS

    o 10.2.2. PLANNED CLINICAL TRIAL SUMMARY

    o 10.2.3. RECENTLY COMPLETED TRIALS

    • 10.3. WITHDRAWN AND DISCONTINUED PROJECTS

    11. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

    • 11.1. EMERGING COMPANIES

    • 11.2. EMERGING COMPANY PROFILES WITH DRUG DESCRIPTIONS AND MILESTONES

    o 11.2.1. COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT EMERGING COMPANIES

    o 11.2.2. STIMULANT DRUG ABUSE DETERRENT EMERGING COMPANIES

    • 11.3. UNIVERSITIES AND INSTITUTES

    12. ABBREVIATIONS

List Of Tables
in Stimulant Abuse Deterrents and Treatments: An Assessment of the Technological, Competitive and R&D Landscape - H1 2020

LIST OF TABLES

TABLE 1: METHAMPHETAMINE V/S COCAINE

TABLE 2: ILLICIT DRUG USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)

TABLE 3: STIMULANT USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)

TABLE 4: COCAINE USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)

TABLE 5: METHAMPHETAMINE USERS EPIDEMIOLOGY (2016), FORECAST (2017-2025)

TABLE 6: COLLABORATION AGREEMENTS, 2000-2018

TABLE 7: LICENSING AGREEMENTS, 2013-2018

TABLE 8: TERMINATION AGREEMENTS

TABLE 9: FUNDING AND CONTRACTS

TABLE 10: PARTNERSHIPS DEALS

TABLE 11: ACQUISITION DEALS

TABLE 12: STAGE OF DEVELOPMENT V/S FORMULATION STRATEGIES

TABLE 13: MOLECULES BELONGING TO TYPE 3 FORMULATION STRATEGY

TABLE 14: MOLECULES BELONGING TO TYPE 2 FORMULATION STRATEGY

TABLE 15: MOLECULE BELONGING TO TYPE 1 FORMULATION STRATEGY

TABLE 16: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PHASE II PIPELINE MOLECULES

TABLE 17: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PHASE I PIPELINE MOLECULES

TABLE 18: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PRECLINICAL STAGE PIPELINE MOLECULES

TABLE 19: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT EARLY R&D PIPELINE MOLECULES

TABLE 20: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT INACTIVE PIPELINE MOLECULES

TABLE 21: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

TABLE 22: PRE-REGISTRATION (FILED) MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE

TABLE 23: PHASE III MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE

TABLE 24: PHASE II MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE

TABLE 25: PHASE I MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE

TABLE 26: PRECLINICAL MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE

TABLE 27: EARLY R&D MOLECULES IN THE STIMULANT DRUG ABUSE PIPELINE

TABLE 28: LIST OF COMPANIES WITH PIPELINE MOLECULES BY STAGE OF DEVELOPMENT

TABLE 29: LIST OF UNIVERSITIES AND INSTITUTES WITH PIPELINE MOLECULES

TABLE 30: STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS, US APPROVAL

TABLE 31: STIMULANT DRUG ABUSE DETERRENT LAUNCH ANALYTICS, EX US APPROVAL

TABLE 32: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS, US APPROVAL

TABLE 33: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT LAUNCH ANALYTICS, EX US APPROVAL

TABLE 34: MN-166 (IBUDILAST) PHASE II CLINICAL TRIAL STUDY DESIGN

TABLE 35: SYN117 (NEPICASTAT) PHASE II CLINICAL TRIAL STUDY DESIGN

TABLE 36: MEASURED VALUE FOR PRIMARY MEASURE- ABSTINENCE

TABLE 37: MEASURED VALUE FOR SECONDARY MEASURE- REDUCTION IN USE

TABLE 38: ONGOING PHASE II CLINICAL TRIALS

TABLE 39: ORADUR-METHYLPHENIDATE ER PHASE III CLINICAL TRIALS STUDY DESIGN

TABLE 40: HLD200 PHASE III CLINICAL TRIALS STUDY DESIGN

TABLE 41: HLD200 SECOND PIVOTAL PHASE III CLINICAL TRIALS STUDY DESIGN

TABLE 42: HLD100 PHASE II TRIAL RESULTS

TABLE 43: RBP-8000 PHASE II CLINICAL TRIALS STUDY DESIGN

TABLE 44: LIST OF UNIVERSITIES AND INSTITUTES

List Of Figures, Charts and Diagrams
in Stimulant Abuse Deterrents and Treatments: An Assessment of the Technological, Competitive and R&D Landscape - H1 2020

LIST OF FIGURES

FIGURE 1: KEY PIPELINE EVENTS, COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT, 2021-2023

FIGURE 2: KEY PIPELINE EVENTS, COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT, 2024-2028

FIGURE 3: KEY PIPELINE EVENTS, STIMULANT DRUG ABUSE DETERRENT, 2018-2034

FIGURE 4: COCAINE USE TRENDS, US, 2002-2016

FIGURE 5: COCAINE USE TRENDS, CANADA, 2004-2009

FIGURE 6: RELATIVE COMPARISION IN PREVALENCE OF COCAINE AND METHAMPHETAMINE DRUG USE, 2009-2013

FIGURE 7: COMPARISION OF COCAINE USERS BY AGE GROUP, 2015-2016

FIGURE 8: COMPARISION OF METHAMPHETAMINE USERS BY AGE GROUP, 2015-2016

FIGURE 9: COCAINE USE, 2015-2016

FIGURE 10: ILLICIT DRUG USERS, US, 2010-2016

FIGURE 11: PREVALENCE OF COCAINE USE, AGE GROUP, CANADA, 2008-2015

FIGURE 12: ILLICIT DRUG USERS AGED 12 AND OLDER; FORECAST (2017-2025)

FIGURE 13: STIMULANT USERS AGED 12 AND OLDER; FORECAST (2017-2025)

FIGURE 14: COCAINE USERS AGED 12 AND OLDER; FORECAST (2017-2025)

FIGURE 15: METHAMPHETAMINE USERS AGED 12 AND OLDER; FORECAST (2017-2025)

FIGURE 16: PHARMACOLOGICAL TREATMENT OPTIONS FOR STIMULANT ADDICTION

FIGURE 17: DEAL ACTIVITY, CNS STIMULANTS AND OPIOIDS

FIGURE 18: STRATEGIES FOR STIMULANT ABUSE DETERRENT FORMULATION

FIGURE 19: ANNUAL PREVALENCE AND NUMBER OF ILLICIT DRUG USERS AT THE GLOBAL LEVEL, 2010

FIGURE 20: ILLICIT DRUG USE AT THE GLOBAL LEVEL, 2008

FIGURE 21: COMPARISION BETWEEN FEMALE AND MALE USERS ATTRIBUTABLE TO DRUG USE DISORDERS, 2005 AND 2015

FIGURE 22: DALY'S COMPARISION BETWEEN FEMALE AND MALE USERS ATTRIBUTABLE TO DRUG USE DISORDERS, 2005 AND 2015

FIGURE 23: ANNUAL PREVALENCE OF THE USE OF COCAINE AND METHAMPHETAMINE BY REGION AND GLOBALLY, 2015

FIGURE 24: COCAINE AND METHAMPHETAMINE DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 25: STIMULANT DRUG ABUSE DETERRENT PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT- COMPANIES

FIGURE 26: STIMULANT DRUG DETERRENT PIPELINE ANALYSIS BY GEOGRAPHY

Additional Details

Publisher

Gervano R A

Publisher Information

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.



GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.



At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Reference

270546 | GERPH500

Number of Pages

187

Report Format

PDF

Gervano R A Reports

This report is published by Gervano R A

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Download Free Report Summary PDF

Stimulant Abuse Deterrents and Treatments: An Assessment of the Technological, Competitive and R&D Landscape - H1 2020 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...